Oncology

Oncology Review CME / CPD 

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 36 (ONC36) Topics Include:  Cancer Screening Protocols, Renal Cancer, Diagnosis and Treatment of Skin Cancer, HCC, Role of CDK4/6 Inhibitors, and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Full Course:
ONC36
Full Course Price:
$580
Short Course:
ONC36A, ONC36B
Short Course Price:
$485
Format:
Available in Audio format.

Course Topics

Highlights from the 2016 Multidisciplinary Head and Neck Cancer Update

Cite independent prognostic factors for overall survival of patients with head and neck cancer; Distinguish between effective and ineffective treatment intensification and de-intensification strategies for patients with oropharyngeal cancer; Assess patients with oral cavity cancer for invasion of muscle, skin, and nerves; Choose appropriate treatment strategies for oral cavity cancer; Consider the use of immunologic therapies for melanoma and head and neck cancer.

Localized and Metastatic Skin Cancer

Identify skin cancers on routine physical examination; Select the appropriate biopsy technique for diagnosis and treatment of skin cancer; Follow a treatment algorithm for evaluation of metastatic melanoma; Evaluate the evidence for the use of single and combination targeted and immune therapies; Recognize and treat adverse effects of current therapies for melanoma.

Cancer Screening and Survivorship

Create cancer screening protocols based on current guidelines; Engage in shared decision making with patients contemplating screening for specific cancers; Counsel pre- and postmenopausal women about options for breast cancer screening; Recognize the importance of lifestyle changes in managing patients with cancer; Consider immunotherapeutic options for treatment of cancer.

Cancer of the Gastrointestinal Tract

Summarize how quality improvement programs associated with the National Cancer Data Base seek to improve delivery of cancer care; Develop strategies for the management of presacral tumors based on the location, histology, malignancy, and size of the lesion; Identify host phenotypes that increase risk for gastric cancer caused by H pylori infection; Recognize patients at risk for colon cancer based on symptoms, family history, and results of screening colonoscopy; Create appropriate management strategies for colon cancer based on location and number of lesions, lymph node involvement, and presence of metastases

Highlights from the 4th Annual Breast Cancer Symposium

Choose effective therapies for treatment of HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; Individualize therapy for patients with breast cancer; Evaluate data on potential new therapies for HER2-positive breast cancer; Screen for and recognize distress in patients diagnosed with breast cancer; Recommend appropriate distress management techniques for patients diagnosed with breast cancer.

Hepatocellular Carcinoma

Analyze current and future epidemiologic trends in risk factors for HCC in the United States; Maximize the effectiveness of surveillance for HCC in clinical practice; Optimize the use of diagnostic evaluation and treatment modalities for patients with HCC; Recognize factors that increase risk for acute cellular rejection or treatment failure following LT; . Identify patients with HCC who are likely to benefit from LT with or without prior downstaging.

Urologic Oncology

Choose evidence-based first- and second- line therapies for patients with renal cancer; Assess evidence on the use of checkpoint inhibitors for patients with renal cancer; Cite clinical trial data that support the use of neoadjuvant chemotherapy in urothelial carcinoma; Distinguish between prognostic and predictive factors for urothelial carcinoma; Apply enhanced recovery after surgery (ERAS) techniques to patients undergoing surgery for cancer.

Highlights from the Eastern North Carolina Lung Cancer Symposium

Identify genetic mutations associated with the development of lung cancer; Counsel patients diagnosed with lung cancer about the importance of smoking cessation; Explain the role that %u03B2-adrenergic receptors of the sympathetic nervous system play in cancer growth.; List immune-mediated adverse events commonly associated with the use of immune checkpoint inhibitors; Choose appropriate treatment for immune-mediated adverse events associated with the use of immune checkpoint inhibitors.

End-of-Life Care

Explain the process of rapid terminal weaning to a patient and family; Manage end-of-life care for a patient who is at risk for stridor during weaning from the ventilator; Work with an interdisciplinary team to create an algorithm for weaning patients from the ventilator during end-of-life care; Perform and interpret the cuff leak test; Create a global palliative dyspnea plan for a patient who is contemplating use of noninvasive positive-pressure ventilation at the end of life.

QUALIFIES FOR END OF LIFE/PALLIATIVE CARE

Endocrine Therapy for Breast Cancer

Illustrate the relationships among patient age, hormonal sensitivity of tumor, and progression-free survival in patients with breast cancer; List the major findings of the ATLAS trial in patients with breast cancer; Use exemestane to improve the treatment of patients with breast cancer; Explain the benefits and risks of treatment with an
aromatase inhibitor for breast cancer; Summarize the role of CDK4/6 inhibitors in treatment of breast cancer.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from the 2016 Multidisciplinary Head and Neck Cancer Update

Cite independent prognostic factors for overall survival of patients with head and neck cancer; Distinguish between effective and ineffective treatment intensification and de-intensification strategies for patients with oropharyngeal cancer; Assess patients with oral cavity cancer for invasion of muscle, skin, and nerves; Choose appropriate treatment strategies for oral cavity cancer; Consider the use of immunologic therapies for melanoma and head and neck cancer.

Cancer Screening and Survivorship

Create cancer screening protocols based on current guidelines; Engage in shared decision making with patients contemplating screening for specific cancers; Counsel pre- and postmenopausal women about options for breast cancer screening; Recognize the importance of lifestyle changes in managing patients with cancer; Consider immunotherapeutic options for treatment of cancer.

Highlights from the 4th Annual Breast Cancer Symposium

Choose effective therapies for treatment of HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; Individualize therapy for patients with breast cancer; Evaluate data on potential new therapies for HER2-positive breast cancer; Screen for and recognize distress in patients diagnosed with breast cancer; Recommend appropriate distress management techniques for patients diagnosed with breast cancer.

Urologic Oncology

Choose evidence-based first- and second- line therapies for patients with renal cancer; Assess evidence on the use of checkpoint inhibitors for patients with renal cancer; Cite clinical trial data that support the use of neoadjuvant chemotherapy in urothelial carcinoma; Distinguish between prognostic and predictive factors for urothelial carcinoma; Apply enhanced recovery after surgery (ERAS) techniques to patients undergoing surgery for cancer.

Highlights from the Eastern North Carolina Lung Cancer Symposium

Identify genetic mutations associated with the development of lung cancer; Counsel patients diagnosed with lung cancer about the importance of smoking cessation; Explain the role that %u03B2-adrenergic receptors of the sympathetic nervous system play in cancer growth.; List immune-mediated adverse events commonly associated with the use of immune checkpoint inhibitors; Choose appropriate treatment for immune-mediated adverse events associated with the use of immune checkpoint inhibitors.

Localized and Metastatic Skin Cancer

Identify skin cancers on routine physical examination; Select the appropriate biopsy technique for diagnosis and treatment of skin cancer; Follow a treatment algorithm for evaluation of metastatic melanoma; Evaluate the evidence for the use of single and combination targeted and immune therapies; Recognize and treat adverse effects of current therapies for melanoma.

Cancer of the Gastrointestinal Tract

Summarize how quality improvement programs associated with the National Cancer Data Base seek to improve delivery of cancer care; Develop strategies for the management of presacral tumors based on the location, histology, malignancy, and size of the lesion; Identify host phenotypes that increase risk for gastric cancer caused by H pylori infection; Recognize patients at risk for colon cancer based on symptoms, family history, and results of screening colonoscopy; Create appropriate management strategies for colon cancer based on location and number of lesions, lymph node involvement, and presence of metastases

Hepatocellular Carcinoma

Analyze current and future epidemiologic trends in risk factors for HCC in the United States; Maximize the effectiveness of surveillance for HCC in clinical practice; Optimize the use of diagnostic evaluation and treatment modalities for patients with HCC; Recognize factors that increase risk for acute cellular rejection or treatment failure following LT; . Identify patients with HCC who are likely to benefit from LT with or without prior downstaging.

End-of-Life Care

Explain the process of rapid terminal weaning to a patient and family; Manage end-of-life care for a patient who is at risk for stridor during weaning from the ventilator; Work with an interdisciplinary team to create an algorithm for weaning patients from the ventilator during end-of-life care; Perform and interpret the cuff leak test; Create a global palliative dyspnea plan for a patient who is contemplating use of noninvasive positive-pressure ventilation at the end of life.

QUALIFIES FOR END OF LIFE/PALLIATIVE CARE

Endocrine Therapy for Breast Cancer

Illustrate the relationships among patient age, hormonal sensitivity of tumor, and progression-free survival in patients with breast cancer; List the major findings of the ATLAS trial in patients with breast cancer; Use exemestane to improve the treatment of patients with breast cancer; Explain the benefits and risks of treatment with an
aromatase inhibitor for breast cancer; Summarize the role of CDK4/6 inhibitors in treatment of breast cancer.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  SurgeryFamily PracticeInternal MedicineObesity and Nutrition.

If you have taken the current Oncology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Oncology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.